Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.
IPO Year:
Exchange: NASDAQ
Website: enveric.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/8/2022 | $7.00 → $0.20 | Buy → Hold | Aegis Capital |
7/8/2021 | $7.00 | Buy | Aegis Capital |
6/28/2021 | $6.00 | Buy | Maxim Group |
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
Psychedelics biotech Enveric Biosciences (NASDAQ:ENVB) announced positive preclinical results of its EB-003 drug candidate to be delivered via oral administration. EB-003 is a new, neuroplastogenic molecule designed to treat serious mental health disorders without the hallucinogenic effect typically associated with DMT (N,N-Dimethyltryptamine) and other psychedelic compounds. The results indicate that oral administration of EB-003 provides significant brain exposure in rodent models at potential therapeutic doses. "We continue to believe that EB-003 is substantially differentiated from the various psychedelic-inspired compounds in development," stated Joseph Tucker, Ph.D., CEO of Enveric.
https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted that MDMA therapies have been proven safe and effective by multiple studies.As an August deadline for the U.S. Food and Drug Administration looms regarding approval for psychedelic therapies, a coalition of well-known scientific researchers took it upon itself to publicize its support for midomafetamine (MDMA)-based treatment for patients with post-traumatic stress disorder.In an online consensus statement, 23 medical doctors and researchers urged the FDA to accept MDMA therapy for PTSD, noting that more than 17 U.S. military veterans commit suicide each day due to
-SEC Filing
Enveric Biosciences (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogenic therapeutics, has been granted a U.S. patent for its drug candidate EB-002. The license, No. 11,945,778, issued by the United States Patent and Trademark Office, includes broad claims for treating brain neurological disorders. This achievement enhances Enveric’s intellectual property protection for EB-002, covering treatment methods for a variety of neurological conditions, including sleep disorders, depression, substance-related disorders and headaches. EB-002, a next-generation psilocin prodrug, is currently under development for neuropsychiatric disorders, initially focusing on anxiety. Signi
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compoundsEnveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the Company is prioritizing the development of EB-003, its first-in-class approach to address difficult-to-treat mental health disorders. EB-003 and other neuropla
https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/"Unfortunately we've seen one service center close down. I imagine there will be more, because very quickly it's going to get oversaturated."By Grant Stringer, Oregon Capital ChronicleA year in, Oregon's experiment with the first regulated psilocybin mushroom market in the world is short on customers.To attract them, advocates say the industry needs to get the word out about its benefits."We think everybody knows that psychedelics can help them because we're in this little bubble. But 99 percent of people have no idea what they could get out of a journey,"
- SEC Filing
Enveric Biosciences (NASDAQ:ENVB) reported it financial results on Wednesday for the first quarter of 2024 ended March 31, 2024. "We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," said Joseph Tucker, Ph.D., director and CEO of Enveric. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to adva
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.78) by 21.79 percent.
Aegis Capital downgraded Enveric Biosciences from Buy to Hold and set a new price target of $0.20 from $7.00 previously
Aegis Capital initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $7.00
Maxim Group initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $6.00
Enveric Biosciences (NASDAQ:ENVB) ("Enveric"), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will deliver a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024. During the presentation, Dr. Tucker will discuss the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, including its lead candidate EB-003, for which the company recently announced data confirming oral bioavailability and significant brain
Enveric and Aries recently announced a Licensing Agreement for patented topical product aimed at treating radiation dermatitis, which impacts approximately two million cancer patients per year and has a market opportunity estimated at $400 million annually Enveric Biosciences (NASDAQ:ENVB) ("Enveric"), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, and Aries Science & Technology ("Aries"), a developer of encapsulation technologies, today announced that Patent No. 12,059,393 was issued on August 13, 2024, to Enveric's wholly-owned subsidiary, Akos Biosciences, Inc. ("Akos"). We believe the newly issued intell
Prioritized EB-003 as lead development candidate. EB-003 is a novel, non-hallucinogenic neuroplastogenic molecule designed to treat severe mental health disorders Announced preclinical results confirming oral bioavailability and significant brain exposure of EB-003, supporting expedited development strategy Expanded business development activities to maximize assets developed using AI-backed drug discovery engine, with multiple deals in advanced stages offering potential to contribute value to stockholders Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the tr
Confirmation of oral bioavailability and significant brain exposure in rodent models supports expedited development of EB-003, with Investigational New Drug (IND) filing and first patient dosed expected in 2025 Enveric Biosciences (NASDAQ:ENVB) ("Enveric"), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced encouraging EB-003 preclinical results indicating the potential for the drug candidate to be delivered via oral administration with significant brain exposure in rodent models at potential therapeutic doses. EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health diso
Aries to clinically develop and market Enveric's patented product for radiation dermatitis Enveric Biosciences (NASDAQ:ENVB) ("Enveric"), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, and Aries Science & Technology ("Aries"), a developer of encapsulation technologies, today announced a licensing agreement for the clinical development of Enveric's patented radiation dermatitis topical product. Radiation dermatitis is a side effect of radiation treatment that impacts roughly two million cancer patients per year and has a market opportunity estimated at $400 million annually. The formulation licensed to Aries
US patent includes broad claims for treating brain neurological disorders Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announces the expansion of protection for potential clinical indications for its EB-002 drug candidate through the issuance of Patent No. 11,945,778 by the United States Patent and Trademark Office. We believe the US patent issuance significantly increases the Company's current intellectual property protection of EB-002 by adding methods of treatment that claim a broad field of brain neurological disorders. The methods o
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ:ENVB). The update note includes information on the Enveric Bioscience's management commentary, recent developments, outlook, and risks. The full research report is available here. Highlights from the report include: EB-003 Elevated to Lead Development Candidate by Enveric Biosciences: Enveric has designated EB-003 as its lead development candidate. EB-003, a pioneering neuroplastogenic molecule, targets severe mental disorders like depression, anxiety, and addiction without
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the Company is prioritizing the development of EB-003, its first-in-class approach to address difficult-to-treat mental health disorders. EB-003 and other n
Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company will participate in the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024. During the conference, Enveric's management team plans to host meetings with potential investment and development partners to discuss and explore potential collaborations for the Company's various promising drug candidates. "We look forward to meeting with our colleagues across the industry at BIO as we continue
Revealed seven classes of promising novel drug candidates discovered using Enveric's Psybrary™ and PsyAI™ drug discovery and artificial intelligence (AI) platforms Launched business development campaign that resulted in the execution of seven non-binding term sheets with four strategic partners that upon entering into definitive agreements and performing pursuant to the terms thereof could potentially total up to approximately $410 Million in milestone payments, plus future royalties Leading non-hallucinogenic neuroplastogen drug candidate, EB-003, continues to advance toward IND filing and subsequent Phase 1 clinical trial Proceeds raised from the exercise of warrants, preferred inve
SC 13G - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G - Enveric Biosciences, Inc. (0000890821) (Subject)
Second biotechnology company to potentially out-license novel compounds from Enveric's portfolio of assets with possible significant milestone payments and royalties Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications for treatment of joint diseases. The term sheets c
30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Kevin Coveney, CPA, to the position of Chief Financial Officer, effective March 13, 2023. Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served as Chief Financial Officer for multiple biotechnology companies. As CFO, Mr. Coveney will be responsibl
Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Lynn Gallant to the position of Vice President, Clinical Operations. Ms. Gallant brings more than 25 years of clinical operations and trial management experience to Enveric and will work alongside Bob Dagher, M.D., Chief Medical Officer, to oversee the ongoing development of the company's EVM201
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of "magic" mushrooms can be used to treat depression. Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. According to CAMH's lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce "sustained antidepressant effects" in individuals living with severe depression. This news comes just days after a major scientific review found "no clear evidence
-- Experienced Leaders Michael Webb, Bevin O'Neil and Frank Pasqualone Join Enveric's Board of Directors -- Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has appointed three new independent directors, Michael D. Webb, President and CEO of CXL Ophthalmics, Bevin O'Neil, Chief Strategy Officer of ECRI, and Frank Pasqualone, recently retired Chief Business Officer of Theravance, to its Board of Directors. "We are delighted to welcome Michael, Bevin and Frank to Enveric's Board at this exciting inflection point in our Company's
NAPLES, Fla., Dec. 6, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced the appointment of Bob Dagher, MD, as Chief Medical Officer, effective immediately. Dr. Dagher brings over 20 years of experience working in clinical development in the pharmaceutical industry for both small and large pharmaceutical companies and as a board-certified physician from the American Board of neurology and psychiatry. He has an extensive therapeutic background
NAPLES, Fla., May 18, 2021 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid (CBD) medicines to improve quality of life for cancer patients, today reported its financial results for the three months ended March 31, 2021. David Johnson, Chairman and Chief Executive Officer, said, "Thus far in 2021, we continued to focus on making progress on our pipeline of support care therapies, bolster our management team and Scientific Advisory Board with talented industry experts and maintain a healthy balance sheet, which as of March 31, 2021 had approximately $23 million in cash. As we approach the s
NAPLES, Fla., April 12, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has appointed Carter Ward as Chief Financial Officer, effective May 15th, 2021. Mr. Ward is replacing John Van Buiten, who is expected to remain in a consulting role with the company, supporting Mr. Ward both during the transition and moving forward. "Mr. Ward will be joining our team with extensive public company leadership experience in life sciences, SEC reporting and the capital markets," said David Johnson, Chairman and CEO of Enveri
NEW YORK, March 18, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the appointment of Dr. Douglas D. Lind to its board of directors. Dr. Lind has more than 30 years of experience working in a variety of life science-related professions, ranging from a former practicing physician, to a senior Wall Street equity research analyst at Morgan Stanley. Dr. Lind currently serves as a co-founder and Managing Partner at Biomark Capital, a Greenwich, Connecticut-based healthcare venture firm, where his investment focus inclu
S-1 - Enveric Biosciences, Inc. (0000890821) (Filer)
8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
10-Q - Enveric Biosciences, Inc. (0000890821) (Filer)
8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
S-3 - Enveric Biosciences, Inc. (0000890821) (Filer)
8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
10-Q - Enveric Biosciences, Inc. (0000890821) (Filer)
3 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
3 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies. Corporate and Business Development Highlights: Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company's extensive portfolio of assets. Signe
Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 Series Announced termination of proposed spin-off of cannabinoid clinical development pipeline to publicly traded company; Enveric now engaging with strategic advisors to identify and pursue alternative value-creating opportunities for cannabinoid assets Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of
The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC') for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos Biosciences, Inc. (‘Akos'),
The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments NAPLES, FL, May 11, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced plans to transfer and spin-off its cannabinoid clinical development pipeline assets to a wholly-owned subsidiary, Acanna Therapeutics Inc. ("Acanna"), by way of dividend to Enveric shareholders. The spin-off transaction will be subject to various condi
NAPLES, Fla., May 3, 2022 /PRNewswire/ - Enveric Biosciences Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly-designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of Enveric common stock held of record as of 5:00 p.m. Eastern Time on May 13, 2022. The outstanding shares of Series C Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, exclusively with respect to a proposal to